Abstract
This protocol outlines a systematic review and meta-analysis designed to evaluate the efficacy and safety of combining Ginseng-plus-Bai-Hu-Tang (GBHT) with conventional Western medicine (CWM) for Type 2 Diabetes Mellitus (T2DM). By synthesizing data from randomized controlled trials (RCTs) across multiple international and Chinese databases, the study aims to provide a rigorous evidence base for this integrative treatment approach.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia, necessitating lifelong management. While conventional Western medicine (CWM) offers standardized treatments, there is significant interest in integrative medicine—combining traditional herbal therapies with modern pharmacology—to enhance glucose control or reduce side effects.
Ginseng-plus-Bai-Hu-Tang (GBHT) is a traditional Chinese herbal formula frequently employed in this context. Despite its widespread use, individual clinical trials often suffer from small sample sizes and inconsistent results. This protocol establishes a framework for a high-level meta-analysis to consolidate existing data and provide a definitive assessment of GBHT's clinical utility.
Methods
The proposed meta-analysis follows a rigorous analytical pipeline to ensure data integrity and minimize bias.
Search Strategy and Study Selection
Comprehensive searches were conducted across major databases, including PubMed, EMBASE, the Cochrane Library, and Chinese databases such as CNKI, WanFang, VIP, and CBM, covering literature up to September 1, 2021. Two independent researchers (Min Zhou and Xiu Liu) screened titles and abstracts to identify relevant RCTs involving human T2DM patients. Disagreements were resolved through consultation with a third researcher (Rong Yu).
Data Extraction and Quality Assessment
Extracted data include author details, publication year, baseline patient characteristics, specific interventions, outcome indicators, and adverse events. The Cochrane Risk of Bias tool will be used to assess the quality of included trials.
Statistical Analysis
Statistical synthesis will be performed using RevMan 5.3.3 and Stata 12.0. Heterogeneity among studies will be assessed using the $I^2$ statistic. A fixed-effects model will be applied if $I^2 < 50%$; otherwise, a random-effects model will be utilized. Publication bias will be evaluated using the Egger test.
Preliminary Results
The initial screening phase identified 381 potential studies. After applying strict inclusion and exclusion criteria—specifically excluding non-RCTs, animal studies, and case reports—the researchers narrowed the selection to 12 high-quality studies. These studies will form the basis of the meta-analysis, evaluating primary outcomes such as the overall effective rate and secondary outcomes including fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hBG), HbA1c, fasting insulin (FINS), and insulin resistance (HOME-RI) levels.
Discussion
This protocol emphasizes the application of rigorous statistical standards to traditional herbal medicine. By pre-registering the study protocol, the researchers ensure transparency and prevent post-hoc data manipulation.
Limitations
A potential limitation is geographic bias, as a significant portion of the data originates from Chinese databases, which may affect the generalizability of findings to non-Asian populations. Furthermore, the review is currently in the protocol stage, with final data synthesis pending.
Conclusion
The upcoming meta-analysis will provide a critical evaluation of GBHT as an adjunctive therapy for T2DM. If the results demonstrate significant improvements in glycemic control and metabolic markers with a favorable safety profile, it could support the integration of GBHT into standard clinical practice and encourage further international multi-center trials.
Summary updated